Literature DB >> 9417048

Specificity of mouse GM2 activator protein and beta-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2.

J A Yuziuk1, C Bertoni, T Beccari, A Orlacchio, Y Y Wu, S C Li, Y T Li.   

Abstract

Tay-Sachs disease, an inborn lysosomal disease featuring a buildup of GM2 in the brain, is caused by a deficiency of beta-hexosaminidase A (Hex A) or GM2 activator. Of the two human lysosomal Hex isozymes, only Hex A, not Hex B, cleaves GM2 in the presence of GM2 activator. In contrast, mouse Hex B has been reported to be more active than Hex A in cleaving GM2 (Burg, J., Banerjee, A., Conzelmann, E., and Sandhoff, K. (1983) Hoppe Seyler's Z. Physiol. Chem. 364, 821-829). In two independent studies, mice with the targeted disruption of the Hexa gene did not display the severe buildup of brain GM2 or the concomitant abnormal behavioral manifestations seen in human Tay-Sachs patients. The results of these two studies were suggested to be attributed to the reported GM2 degrading activity of mouse Hex B. To clarify the specificity of mouse Hex A and Hex B and to better understand the observed results of the mouse model of Tay-Sachs disease, we have purified mouse liver Hex A and Hex B and also prepared the recombinant mouse GM2 activator. Contrary to the findings of Burg et al., we found that the specificities of mouse Hex A and Hex B toward the catabolism of GM2 were not different from the corresponding human Hex isozymes. Mouse Hex A, but not Hex B, hydrolyzes GM2 in the presence of GM2 activator, whereas GM2 is refractory to mouse Hex B with or without GM2 activator. Importantly, we found that, in contrast to human GM2 activator, mouse GM2 activator could effectively stimulate the hydrolysis of GA2 by mouse Hex A and to a much lesser extent also by Hex B. These results provide clear evidence on the existence of an alternative pathway for GM2 catabolism in mice by converting GM2 to GA2 and subsequently to lactosylceramide. They also provide the explanation for the lack of excessive GM2 accumulation in the Hexa gene-disrupted mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9417048     DOI: 10.1074/jbc.273.1.66

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Degradation of G(M1) and G(M2) by mammalian sialidases.

Authors:  S C Li; Y T Li; S Moriya; T Miyagi
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

2.  Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.

Authors:  Subha Karumuthil-Melethil; Sahana Nagabhushan Kalburgi; Patrick Thompson; Michael Tropak; Michael D Kaytor; John G Keimel; Brian L Mark; Don Mahuran; Jagdeep S Walia; Steven J Gray
Journal:  Hum Gene Ther       Date:  2016-07       Impact factor: 5.695

3.  Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease.

Authors:  Rena C Baek; Douglas R Martin; Nancy R Cox; Thomas N Seyfried
Journal:  Lipids       Date:  2008-11-26       Impact factor: 1.880

4.  Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.

Authors:  Hiromi Akeboshi; Yasunori Chiba; Yoshiko Kasahara; Minako Takashiba; Yuki Takaoka; Mai Ohsawa; Youichi Tajima; Ikuo Kawashima; Daisuke Tsuji; Kohji Itoh; Hitoshi Sakuraba; Yoshifumi Jigami
Journal:  Appl Environ Microbiol       Date:  2007-06-08       Impact factor: 4.792

5.  Construction of a hybrid β-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivo.

Authors:  Michael B Tropak; Sayuri Yonekawa; Subha Karumuthil-Melethil; Patrick Thompson; Warren Wakarchuk; Steven J Gray; Jagdeep S Walia; Brian L Mark; Don Mahuran
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-02       Impact factor: 6.698

Review 6.  Animal models of GM2 gangliosidosis: utility and limitations.

Authors:  Cheryl A Lawson; Douglas R Martin
Journal:  Appl Clin Genet       Date:  2016-07-20

Review 7.  New Approaches to Tay-Sachs Disease Therapy.

Authors:  Valeriya V Solovyeva; Alisa A Shaimardanova; Daria S Chulpanova; Kristina V Kitaeva; Lisa Chakrabarti; Albert A Rizvanov
Journal:  Front Physiol       Date:  2018-11-20       Impact factor: 4.566

8.  In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.

Authors:  Incilay Sinici; Sayuri Yonekawa; Ilona Tkachyova; Steven J Gray; R Jude Samulski; Warren Wakarchuk; Brian L Mark; Don J Mahuran
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

9.  GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.

Authors:  Seçil Akyıldız Demir; Zehra Kevser Timur; Nurselin Ateş; Luis Alarcón Martínez; Volkan Seyrantepe
Journal:  J Neuroinflammation       Date:  2020-09-20       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.